as 07-25-2025 4:00pm EST
Stocks
Jade Biosciences Inc is focused on developing therapies to address critical unmet needs in autoimmune diseases. Its asset, JADE-001, will target the anti-A PRoliferation-Inducing Ligand (APRIL) pathway for immunoglobulin A (IgA) nephropathy, with Investigational New Drug Application-enabling studies underway and initiation of a first-in-human trial. Jade's pipeline also includes two undisclosed optimized antibody discovery programs, JADE-002 and JADE-003, currently in preclinical development. Jade was launched based on assets licensed from Paragon Therapeutics, an antibody discovery engine founded by Fairmount.
Founded: | 2024 | Country: | United States |
Employees: | N/A | City: | WALTHAM |
Market Cap: | 290.1M | IPO Year: | N/A |
Target Price: | $15.50 | AVG Volume (30 days): | 397.1K |
Analyst Decision: | Strong Buy | Number of Analysts: | 2 |
Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
EPS: | -18.79 | EPS Growth: | N/A |
52 Week Low/High: | $1.61 - $13.50 | Next Earning Date: | 08-05-2025 |
Revenue: | N/A | Revenue Growth: | N/A |
Revenue Growth (this year): | N/A | Revenue Growth (next year): | N/A |
JBIO Breaking Stock News: Dive into JBIO Ticker-Specific Updates for Smart Investing
Yahoo Finance
16 days ago
GlobeNewswire
18 days ago
GlobeNewswire
25 days ago
Barchart
a month ago
GlobeNewswire
2 months ago
GlobeNewswire
2 months ago
GlobeNewswire
2 months ago
GlobeNewswire
2 months ago
The information presented on this page, "JBIO JADE BIOSCIENCES INC - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.